Expert Opinion on Drug Metabolism & Toxicology

Papers
(The TQCC of Expert Opinion on Drug Metabolism & Toxicology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Probing the mechanism of reduced in vivo potency of insulin detemir113
Comorbidities and the right dose: antipsychotics106
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update68
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects60
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata57
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury50
Hormones, microbes, and PrEP drugs in the female genital tract45
Guidance for interactions between antiseizure medications32
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis32
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria27
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine27
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database25
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer23
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis23
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update21
In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals20
Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease19
Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase19
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury19
The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study19
Bioactivity descriptors for in vivo toxicity prediction: now and the future18
Correction17
Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase17
A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition17
A comprehensive review of the efficacy and safety of ertugliflozin17
Clinical pharmacokinetics and pharmacodynamics of nicardipine; a systematic review16
Drug-drug interactions between psychotropic medications and oral contraceptives16
Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen15
Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders15
Pharmacokinetic considerations surrounding triple therapy for uncontrolled asthma15
Physiologically based pharmacokinetic modeling in obesity: applications and challenges15
A high-throughput liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of p -cresol sulfate, p -cresol14
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care – an overview14
The impact of advanced age on anticoagulant therapy for acute venous thromboembolism13
Risk factors and prediction for DILI in clinical practice12
Evaluating pharmacokinetic drug–drug interactions of direct oral anticoagulants in patients with renal dysfunction12
Population pharmacokinetic–pharmacodynamic analysis of givinostat12
Current state-of-the-art approaches for mass spectrometry in clinical toxicology: an overview12
Integrative approaches for studying the role of noncoding RNAs in influencing drug efficacy and toxicity12
Drug absorption from oral formulations in patients with short bowel syndrome: a comprehensive update of the literature12
Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation12
Recent progress in machine learning approaches for predicting carcinogenicity in drug development12
Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies11
Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjec11
Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review11
The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity – a review of pharmacological and clinical data11
Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction10
CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study10
Development and application of a population pharmacokinetic model repository for caffeine dose tailoring in preterm infants10
An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease9
Bioequivalence of generic and branded ibrutinib capsules in healthy Chinese volunteers under fasting and fed conditions: a randomized, four-period, fully replicated, crossover study9
The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications9
Analysis of drug–drug interactions in patients with HIV and metabolic syndrome9
Antisense oligonucleotides: absorption, distribution, metabolism, and excretion9
PBPK models of the female reproductive tract: current and future analysis9
Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature9
Safety of concomitant use of oral anticoagulants and antidiabetic drugs: a systematic review of observational studies9
Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modeling9
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes9
In-silico approaches to assessing multiple high-level drug-drug and drug-disease adverse drug effects9
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis9
Switching from cangrelor to oral P2Y 12 inhibitors: a focused review on drug–drug interactions9
Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults8
Cardiomyocyte-specific CYP2J2 and its therapeutic implications8
Interactions between antiepileptic drugs and direct oral anticoagulants for primary and secondary stroke prevention8
Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson’s disease8
Overcoming barriers to machine learning applications in toxicity prediction8
Positioning the new drugs for migraine8
Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers8
High-throughput PBTK models for in vitro to in vivo extrapolation8
Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids7
Machine learning and deep learning approaches for enhanced prediction of hERG blockade: a comprehensive QSAR modeling study7
Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease lead to depression?7
Drug interactions in people with HIV treated with antivirals for other viral illnesses7
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine7
The role of pharmacogenetics in the treatment of anxiety disorders and the future potential for targeted therapeutics7
Toxic metabolites and metabolic soft spots of celastrol based on glutathione metabolic capture and high-resolution mass spectrometry7
Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healt7
Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications7
The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review6
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout6
Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with the metabolism: the consequences on mitochondrial dysfunction and oxi6
DILI prediction in drug development: present and future6
Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage6
Drug dosing optimization in critically ill children under continuous renal replacement therapy: from basic concepts to the bedside model informed precision dosing6
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study6
Considerations for drug–drug interactions between long-acting antiretrovirals and immunosuppressants for solid organ transplantation6
Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability6
Pharmacokinetic studies in dialysis-dependent patients: limited data availability6
Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics6
Managing intoxications with nicotine-containing e-liquids6
Regulation of cyclophosphamide induced hepatotoxicity by REV-ERBα modifiers6
Drug–drug interactions in HIV-infected patients receiving chemotherapy6
0.059514999389648